KR20090071668A - 암치료에 유용한 폴로형 키나아제 억제제로서 프테리딘 유도체 - Google Patents

암치료에 유용한 폴로형 키나아제 억제제로서 프테리딘 유도체 Download PDF

Info

Publication number
KR20090071668A
KR20090071668A KR1020097010620A KR20097010620A KR20090071668A KR 20090071668 A KR20090071668 A KR 20090071668A KR 1020097010620 A KR1020097010620 A KR 1020097010620A KR 20097010620 A KR20097010620 A KR 20097010620A KR 20090071668 A KR20090071668 A KR 20090071668A
Authority
KR
South Korea
Prior art keywords
amino
cyclopentyl
ethyl
methyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020097010620A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 페스투스 차알스 모패트
산제이 래티럴 패텔
스테펜 존 데이비스
케니트 윌리암 존 베이커
올리버 제임스 필립스
Original Assignee
크로마 데러퓨릭스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0621205A external-priority patent/GB0621205D0/en
Priority claimed from GB0715614A external-priority patent/GB0715614D0/en
Application filed by 크로마 데러퓨릭스 리미티드 filed Critical 크로마 데러퓨릭스 리미티드
Publication of KR20090071668A publication Critical patent/KR20090071668A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020097010620A 2006-10-25 2007-10-19 암치료에 유용한 폴로형 키나아제 억제제로서 프테리딘 유도체 Withdrawn KR20090071668A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0621205.4 2006-10-25
GB0621205A GB0621205D0 (en) 2006-10-25 2006-10-25 Inhibitors of PLK
GB0715614.4 2007-08-10
GB0715614A GB0715614D0 (en) 2007-08-10 2007-08-10 Inhibitors of plk

Publications (1)

Publication Number Publication Date
KR20090071668A true KR20090071668A (ko) 2009-07-01

Family

ID=38896021

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097010620A Withdrawn KR20090071668A (ko) 2006-10-25 2007-10-19 암치료에 유용한 폴로형 키나아제 억제제로서 프테리딘 유도체

Country Status (13)

Country Link
US (1) US20100216802A1 (enExample)
EP (1) EP2079743B1 (enExample)
JP (1) JP2010507639A (enExample)
KR (1) KR20090071668A (enExample)
AT (1) ATE542820T1 (enExample)
AU (1) AU2007310604B2 (enExample)
BR (1) BRPI0718120A2 (enExample)
CA (1) CA2665736A1 (enExample)
EA (1) EA200900593A1 (enExample)
IL (1) IL198082A0 (enExample)
MX (1) MX2009004244A (enExample)
NZ (1) NZ577153A (enExample)
WO (1) WO2008050096A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020111325A1 (ko) * 2018-11-28 2020-06-04 국립암센터 Plk1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0619753D0 (en) * 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
CA2668070A1 (en) * 2006-10-30 2008-05-08 Chroma Therapeutics Ltd. Hydroxamates as inhibitors of histone deacetylase
WO2008076392A2 (en) 2006-12-14 2008-06-26 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinase inhibitors
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
GB0807451D0 (en) * 2008-04-24 2008-05-28 Chroma Therapeutics Ltd Inhibitors of PLK
AU2009271658B2 (en) 2008-06-23 2014-04-10 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
WO2010008459A1 (en) * 2008-06-23 2010-01-21 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
WO2011026241A1 (en) * 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Substituted heterocyclic derivatives for the treatment of pain and epilepsy
CN102020643A (zh) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
CN104781235B (zh) 2012-10-17 2016-12-21 色品疗法有限公司 N-[2-{4-[6-氨基-5-(2,4-二氟苯甲酰)-2-氧代吡啶-1(2h)-基]-3,5-二氟苯基}乙基]-l-丙氨酸叔丁酯或其盐、水合物或溶剂合物
US10208023B2 (en) 2013-03-01 2019-02-19 Mark G. DeGiacomo Heterocyclic inhibitors of the sodium channel
US9566280B2 (en) 2014-01-28 2017-02-14 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
EP3099693A4 (en) 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
KR20160111520A (ko) * 2014-01-31 2016-09-26 다나-파버 캔서 인스티튜트 인크. 디히드로프테리디논 유도체 및 그의 용도
US10150756B2 (en) 2014-01-31 2018-12-11 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
PE20181287A1 (es) 2015-09-11 2018-08-07 Dana Farber Cancer Inst Inc Ciano tienotriazolpirazinas y usos de las mismas
US10913752B2 (en) 2015-11-25 2021-02-09 Dana-Farber Cancer Institute, Inc. Bivalent bromodomain inhibitors and uses thereof
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
EP3833353A4 (en) * 2018-08-10 2022-08-24 Yale University Small-molecule pi5p4k alpha/beta inhibitors and methods of treatment using same
CN111039944B (zh) 2018-10-12 2021-11-23 中国科学院合肥物质科学研究院 Mst1激酶抑制剂及其用途
CN115947728B (zh) * 2021-10-09 2024-01-09 沈阳药科大学 含磺酰基的二氢喋啶酮衍生物及其应用
EP4479042A1 (en) 2022-02-18 2024-12-25 Massachusetts Institute Of Technology Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization
CN118047779B (zh) * 2022-11-09 2025-02-11 沈阳药科大学 含苯联杂芳基的二氢喋啶酮衍生物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
WO2006021547A1 (de) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinone als plk (polo like kinase) inhibitoren
EP1784406A1 (de) * 2004-08-27 2007-05-16 Boehringer Ingelheim International GmbH Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020111325A1 (ko) * 2018-11-28 2020-06-04 국립암센터 Plk1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
CA2665736A1 (en) 2008-05-02
EP2079743A1 (en) 2009-07-22
AU2007310604A1 (en) 2008-05-02
ATE542820T1 (de) 2012-02-15
EA200900593A1 (ru) 2010-06-30
EP2079743B1 (en) 2012-01-25
US20100216802A1 (en) 2010-08-26
JP2010507639A (ja) 2010-03-11
NZ577153A (en) 2012-02-24
BRPI0718120A2 (pt) 2013-11-12
MX2009004244A (es) 2009-05-14
WO2008050096A1 (en) 2008-05-02
AU2007310604B2 (en) 2012-02-02
IL198082A0 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
KR20090071668A (ko) 암치료에 유용한 폴로형 키나아제 억제제로서 프테리딘 유도체
US20220370416A1 (en) Compounds and methods for targeted degradation of kras
JP7286539B2 (ja) タウタンパク質標的化ｐｒｏｔａｃ、および関連使用方法
CN101273030B (zh) 丙型肝炎病毒的大环抑制剂
US9428464B2 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CN106061976B (zh) 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
US9603889B2 (en) IAP antagonists
WO2023025116A1 (zh) 杂环类衍生物、其制备方法及其医药上的用途
CN115697990A (zh) 基于吲唑的化合物和相关使用方法
CN110023304A (zh) 钙蛋白酶调节剂及其治疗用途
JPWO2018102067A5 (enExample)
CN119301132A (zh) 用于治疗癌症的卤代吲哚大环化合物
HK1211579A1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
JP2020537677A (ja) ジヒドロピリミジン化合物、及び医薬におけるその使用
US10329324B2 (en) Indoline compounds as granzyme B inhibitors
KR20130113950A (ko) Ｍｔｏｒ 선택적 키나아제 억제제
KR20230142745A (ko) Cdk2 억제제 및 그의 사용 방법
US20230002396A1 (en) Therapeutic compounds
CN102395584A (zh) 用于代谢疾病治疗的化合物
CN111434662A (zh) 卤代烯丙基胺类化合物及其应用
CN101541800A (zh) 用于治疗癌症的作为plk抑制剂的蝶啶衍生物
JP2023549187A (ja) 貧血およびがんの処置のためのｖｈｌ阻害剤としての１－（２－（４－シクロプロピル－１ｈ－１，２，３－トリアゾール－１－イル）アセチル）－４－ヒドロキシ－ｎ－（ベンジル）ピロリジンｅ－２－カルボキサミド誘導体
WO2021218997A1 (zh) 取代的氮杂五元环类化合物及其在药物中的应用
CN113767102A (zh) 具有抗乙型肝炎病毒(hbv)活性的新的苯基和吡啶基脲类化合物
CN115151544B (zh) β-内酰胺酶抑制剂及其制备

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090525

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid